“Drug Regimen Review (DRR)”, performed by pharmacists, has been a requirement since 1974. This important clinical role has been shown to promote optimal drug therapy. Now, newly labeled F756 continues the mandate that DRR be performed at least monthly by a pharmacist, but further clarifies that the DRR must include a review of the resident’s medical chart.
This F-Tag also requires that consultant pharmacists document any drug therapy “irregularities” and report the specifics of each irregularity to the attending physician, the medical director and the director of nursing.
